Stroke is the second leading cause of death worldwide and a major cause of long-term disability.
More high-quality years of life are lost due to stroke than to any other disease. The disability caused by the disease can be significantly reduced by efficient treatment of those affected.
Stroke kills brain cells
A stroke occurs when a blood clot blocks a vessel or artery, or when a blood vessel breaks, interrupting blood flow to an area of the brain. When a stroke occurs, it kills brain cells in the immediate area. This can happen anytime from a few minutes after the stroke starts to a few hours later.
Stroke forum – dedicated to improving stroke therapy
Find out more on Boehringer Ingelheim’s corporate website on stroke:Stroke forum
Products
Actilyse® (alteplase)
Indicated for thrombolytic treatment in acute ischaemic stroke.
Actilyse® is also registered for the indication acute myocardial infarction which can be found under “Acute Coronary Disease”.
Aggrenox®, Asasantin®Retard (dipyridamole/ASA) Indicated to reduce the risk of stroke in patients who have had transient ischaemia of the brain or completed ischaemic stroke due to thrombosis.
Online Activities
Actilyse® – product website
International website (healthcare professionals)
Aggrenox/Asasantin® – product website
International website (healthcare professionals)
Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Our business consists largely of Human pharmaceuticals (consisting of Prescription Medicines, Consumer Health Care and Biopharmaceuticals) as well as Pharma Chemicals and Animal Health.
